ATE420956T1 - Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten - Google Patents

Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten

Info

Publication number
ATE420956T1
ATE420956T1 AT97954089T AT97954089T ATE420956T1 AT E420956 T1 ATE420956 T1 AT E420956T1 AT 97954089 T AT97954089 T AT 97954089T AT 97954089 T AT97954089 T AT 97954089T AT E420956 T1 ATE420956 T1 AT E420956T1
Authority
AT
Austria
Prior art keywords
accessory molecule
immunomodulation
molecule ligands
treatment
autoimmune diseases
Prior art date
Application number
AT97954089T
Other languages
English (en)
Inventor
Thomas Kipps
Sanjai Sharma
Mark Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE420956T1 publication Critical patent/ATE420956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT97954089T 1996-12-09 1997-12-08 Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten ATE420956T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Publications (1)

Publication Number Publication Date
ATE420956T1 true ATE420956T1 (de) 2009-01-15

Family

ID=26708033

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09164341T ATE547524T1 (de) 1996-12-09 1997-12-08 Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten
AT97954089T ATE420956T1 (de) 1996-12-09 1997-12-08 Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09164341T ATE547524T1 (de) 1996-12-09 1997-12-08 Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten

Country Status (16)

Country Link
US (3) US7070771B1 (de)
EP (4) EP1806360A3 (de)
JP (1) JP4015201B2 (de)
CN (1) CN1221662C (de)
AT (2) ATE547524T1 (de)
AU (1) AU5795798A (de)
BR (1) BR9714004A (de)
CA (2) CA2707726C (de)
DE (1) DE69739220D1 (de)
DK (1) DK0948614T3 (de)
ES (1) ES2321246T3 (de)
IL (3) IL130247A0 (de)
NO (2) NO327411B1 (de)
NZ (1) NZ336092A (de)
PT (1) PT948614E (de)
WO (1) WO1998026061A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2369820A1 (en) * 1999-04-16 2000-10-26 Frank Dicker Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20050214311A1 (en) * 2002-02-25 2005-09-29 Screaton Gavin R Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
EP2139913A4 (de) * 2007-03-08 2011-09-21 Mayo Foundation Einleitung von immunvermitteltem tumorzelltod
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
WO2015148879A1 (en) * 2014-03-27 2015-10-01 The Regents Of The University Of Michigan Cancer immunotherapy compositions and methods
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112725379A (zh) * 2021-01-27 2021-04-30 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US5095096A (en) 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
DK0491878T3 (da) 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
EP1239043A3 (de) 1992-03-30 2003-01-02 Immunex Corporation Fusionsproteine enthaltend Tumor Necrosis Factor-Rezeptor
CZ283533B6 (cs) 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
EP0615451B1 (de) 1992-05-26 2005-12-07 Immunex Corporation Neue zytokine die cd30 binden
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DK0679191T3 (da) 1993-01-22 2004-04-13 Immunex Corp Påvisning og behandling af mutationer i et CD40-ligand-gen
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
JPH09507074A (ja) 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
ATE387458T1 (de) 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
DK0763057T3 (da) 1994-04-28 2006-03-27 Boehringer Ingelheim Pharma Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
CA2195665A1 (en) 1994-07-22 1996-02-08 Robert Frederick Geoffrey Booth Pharmaceutical compositions comprising a chimaeric tnf binding protein
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
US6951919B1 (en) 1997-09-17 2005-10-04 Mochida Pharmaceutical Co., Ltd. Fas ligand derivative
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
US7524944B2 (en) 2009-04-28
EP0948614A2 (de) 1999-10-13
CA2274498A1 (en) 1998-06-18
PT948614E (pt) 2009-04-20
NO327411B1 (no) 2009-06-22
CN1221662C (zh) 2005-10-05
EP2287309A1 (de) 2011-02-23
US7070771B1 (en) 2006-07-04
JP2001505782A (ja) 2001-05-08
DK0948614T3 (da) 2009-05-11
US20060183199A1 (en) 2006-08-17
DE69739220D1 (de) 2009-03-05
EP1806360A3 (de) 2007-12-12
NZ336092A (en) 2001-09-28
WO1998026061A3 (en) 1998-11-19
CA2707726C (en) 2013-10-22
EP2145958B1 (de) 2012-02-29
ES2321246T3 (es) 2009-06-03
ATE547524T1 (de) 2012-03-15
IL130247A0 (en) 2000-06-01
US7906638B2 (en) 2011-03-15
CA2707726A1 (en) 1998-06-18
EP0948614B1 (de) 2009-01-14
NO331434B1 (no) 2011-12-27
NO992756D0 (no) 1999-06-07
JP4015201B2 (ja) 2007-11-28
US20100267129A1 (en) 2010-10-21
WO1998026061A2 (en) 1998-06-18
NO20074906L (no) 1999-08-09
AU5795798A (en) 1998-07-03
CA2274498C (en) 2010-06-29
CN1246892A (zh) 2000-03-08
BR9714004A (pt) 2000-05-02
EP1806360A2 (de) 2007-07-11
NO992756L (no) 1999-08-09
IL130247A (en) 2008-03-20
IL178306A0 (en) 2007-02-11
EP2145958A1 (de) 2010-01-20

Similar Documents

Publication Publication Date Title
ATE420956T1 (de) Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
CY1105240T1 (el) 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
DE69940964D1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
WO2004110345A8 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
ATE357518T1 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
ATE280226T1 (de) Genetische marker für brust und eierstockkrebs
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
DE3587939D1 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
ES8302778A1 (es) Un procedimiento para producir un polipeptido antiviral.
DE69821011D1 (de) Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
ATE361933T1 (de) 5' ests für sekretierte proteine aus gehirngeweben
DE60043125D1 (de) Zusammensetzungen und Verfahren für die Tumor-Behandlung
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE374619T1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE439431T1 (de) Zusammenstellung und verfahren zur diagnose von tumoren
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
DE69519924T2 (de) Gammaglobuline enthaltende immunotherapeutische präparate für die behandlung von krebskrankheiten
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
DE69130117D1 (de) Methode und Zusammensetzungen zur Behandlung von bösartigen Entartungen, die in Zusammenhang mit einer Proteinkinase stehen
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
ATE516364T1 (de) Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties